Prof. Xiaofei Wang

Duke University Medical Center, USA

Email: [email protected]

Qualifications

2003 Ph.D., University of North Carolina

1999 M.Sc., University of North Carolina

1993 M.Sc., Peking University

1990 B.Sc., East China Normal University

Publications (selected)

1. Higgins, K. A., Hu, C., Ross, H. J., et al. (2026). Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. Journal of Clinical Oncology, 44(8).
2. Oduah, E., Antonia, S. J., Clarke, J. J., et al. (2025). Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer. Journal of Clinical Oncology, 43(16_suppl), Article TPS8118.
3. Yu, S. L., Wang, X., Wen, S., et al. (2025). Real-world comparison of lutetium-177 vipivotide tetraxetan in advanced castration resistant metastatic prostate cancer patients in Appalachia. Journal of Clinical Oncology, 43(16_suppl), Article e17026.
4. Ross, H. J., Kozono, D., Wang, X. F., et al. (2024). Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer A Phase II Nonrandomized Controlled Trial. JAMA Oncology, 10(9), 1212–1219.
5. Mansfield, A. S., Wang, X. F., Wigle, D. A., et al. (2024). Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101). Journal of Clinical Oncology, 42(16_suppl), Article TPS8125.
6. Ross, H. J., Kozono, D. E., Mix, M. D., et al. (2024). A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57). Journal of Clinical Oncology, 42(16_suppl), Article TPS8123.
7. Mansfield, A. S., Wang, X. F., Wigle, D. A., et al. (2023). Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101). Journal of Clinical Oncology, 41(16_suppl), Article TPS8602.
8. Saltos, A. N., Arrowood, C., Beasley, G., et al. (2023). A phase 1 first-in-human study of interferon beta (IFNb) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology, 41(16_suppl), 2569.
9. Saltos, A. N., Arrowood, C., Beasley, G., et al. (2023). A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology, 41(16_suppl), Article 2569.
10. Saltos, A. N., Arrowood, C., Beasley, G., et al. (2023). A phase 1 first-in-human study of MEM-288 oncolytic virus in solid tumors including non-small cell lung cancer (NSCLC): impact on tumor and systemic T cell immunity. Cancer Research, 83(8_suppl), Article CT103.
11. Pang, H., Leung, T. H., Ho, J. C. M., et al. (2022). Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer immunotherapy studies. Journal of Clinical Oncology, 40(16_suppl), Article e16222.
12. Bogart, J. A., Wang, X. F., Masters, G. A., et al. (2021). Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538. Journal of Clinical Oncology, 39(15_suppl), 8505.
13. Ross, H. J., Kozono, D. E., Urbanic, J. J., et al. (2021). AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 39(15_suppl), 8513.
14. Clarke, J. M., Wang, X. F., Gu, L., et al. (2020). Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 38(15_suppl), Article e21683.
15. Ross, H. J., Hu, C., Higgins, K. A., et al. (2020). NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer. Journal of Clinical Oncology, 38(15_suppl), Article TPS9082.
16. Ross, H. J., Kozono, D. E., Urbanic, J. J., et al. (2020). AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 38(15_suppl), 9045.
17. Dudek, A. Z., Wang, X. F., Gu, L., et al. (2019). Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance). Journal of Clinical Oncology, 37(15_suppl), 8517.
18. Hensing, T. A., Wang, X. F., Gao, J., et al. (2019). Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09). Journal of Clinical Oncology, 37(15_suppl), 9088.
19. Stinchcombe, T., Doebele, R. C., Wang, X. F., et al. (2019). Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK plus non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 37(15_suppl), 9027.
20. Yang, C.-F. J., Chan, D. Y., Shah, S. A., et al. (2018). Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer. Annals of Surgery, 268(6), 1105–1112.

Profile Details
https://medschool.duke.edu/profile/xiaofei-wang
https://www.researchgate.net/scientific-contributions/Xiaofei-Wang-2284078167

WOS ResearcherID: ITC-8495-2023